4,906 Shares of Incyte Corporation $INCY Purchased by Wedbush Securities Inc.

Wedbush Securities Inc. acquired a new stake in Incyte Corporation (NASDAQ:INCY) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 4,906 shares of the biopharmaceutical company’s stock, valued at approximately $595,000.

A number of other hedge funds also recently bought and sold shares of the business. Fiduciary Financial Advisors acquired a new position in shares of Incyte during the 2nd quarter worth approximately $26,000. Continuum Advisory LLC purchased a new stake in shares of Incyte in the second quarter valued at approximately $36,000. Quantbot Technologies LP purchased a new stake in shares of Incyte in the second quarter valued at approximately $52,000. Parkside Financial Bank & Trust increased its holdings in shares of Incyte by 49.0% in the second quarter. Parkside Financial Bank & Trust now owns 727 shares of the biopharmaceutical company’s stock valued at $82,000 after purchasing an additional 239 shares during the last quarter. Finally, Contravisory Investment Management Inc. acquired a new stake in shares of Incyte in the third quarter valued at approximately $82,000. Institutional investors and hedge funds own 96.97% of the company’s stock.

Insider Activity at Incyte

In related news, insider Pablo Cagnoni sold 10,801 shares of the stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $125.56, for a total transaction of $1,356,173.56. Following the completion of the transaction, the insider owned 183,200 shares of the company’s stock, valued at approximately $23,002,592. This trade represents a 5.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrick Mayes sold 41,899 shares of Incyte stock in a transaction that occurred on Friday, July 31st. The shares were sold at an average price of $119.46, for a total transaction of $5,005,254.54. Following the completion of the sale, the executive vice president owned 61,441 shares of the company’s stock, valued at $7,339,741.86. This trade represents a 40.54% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 55,342 shares of company stock worth $6,659,208. Company insiders own 16.20% of the company’s stock.

Incyte Stock Performance

NASDAQ:INCY opened at $116.60 on Wednesday. Incyte Corporation has a 52 week low of $84.02 and a 52 week high of $132.60. The stock’s fifty day moving average is $120.99 and its two-hundred day moving average is $107.96.

Incyte (NASDAQ:INCY) last released its quarterly earnings results on Tuesday, July 28th. The biopharmaceutical company reported $3.09 earnings per share for the quarter, topping analysts’ consensus estimates of $2.15 by $0.94. The business had revenue of $1.67 billion for the quarter, compared to analysts’ expectations of $1.50 billion. The business’s revenue for the quarter was up 37.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.57 earnings per share. On average, equities research analysts anticipate that Incyte Corporation will post 1.97 EPS for the current fiscal year.

Trending Headlines about Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: New ESMO 2026 data for INCB161734 and INCA33890 advanced Incyte’s gastrointestinal-cancer portfolio. INCB161734 reportedly produced lasting tumor responses in pancreatic cancer, positioning Incyte as a credible competitor in the KRAS G12D treatment race. EMSO 2026: Incyte a firm contender in G12D pancreatic cancer race as early candidate shines
• Positive Sentiment: Incyte said it is “neck and neck” with Revolution Medicines in the KRAS G12D pancreatic-cancer market, suggesting meaningful commercial potential if its candidate continues to demonstrate durable efficacy. ESMO: Why Incyte sees itself neck and neck with RevMed in KRAS G12D pancreatic cancer race
• Positive Sentiment: H.C. Wainwright reiterated its Buy rating and $152 price target, citing the pancreatic-cancer data as evidence that Incyte may be undervalued. Incyte KRAS G12D PDAC data underscore undervalued opportunity
• Positive Sentiment: Incyte and Genmab agreed to evaluate a three-drug combination for first-line KRAS G12D-mutated metastatic colorectal cancer, expanding the potential reach of the companies’ targeted-oncology collaboration. Incyte and Genmab collaborate to develop a new colorectal cancer therapy
• Neutral Sentiment: Morgan Stanley maintained a Hold rating. The firm sees promise in Incyte’s oncology pipeline but believes long-term development execution and program timing risks temper the near-term investment case. Balanced view on Incyte

Analyst Upgrades and Downgrades

INCY has been the topic of a number of analyst reports. Mizuho lifted their price objective on Incyte from $121.00 to $137.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Wells Fargo & Company upped their target price on Incyte from $116.00 to $128.00 and gave the company an “equal weight” rating in a report on Thursday, October 1st. Canaccord Genuity Group initiated coverage on Incyte in a research note on Thursday, August 20th. They issued a “buy” rating and a $152.00 target price for the company. Guggenheim lifted their price target on Incyte from $136.00 to $150.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Finally, UBS Group reiterated a “neutral” rating and set a $127.00 price target on shares of Incyte in a report on Monday, October 5th. Twelve equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $131.43.

About Incyte

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.